Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
2025-07-28 11:04:27
HapX in Arthroderma benhamiae: Iron Regulation Without Virulence LossX regulates iron metabolism in A. benhamiae by controlling siderophore production and repressing iron-dependent genes, yet is dispensable for keratin-based virulence, suggesting compensatory iron acquisition strategies.
2025-07-28 10:51:40
Microsporum canis Siderophores Identified as Ferrichrome and FerricrocinThis study characterized the siderophores produced by Microsporum and Trichophyton species, revealing that M. canis secretes ferrichrome and ferricrocin under iron-limited conditions, indicating siderophore pathways as exploitable therapeutic targets.
2025-07-27 18:07:28
Microsporum canis Whole Genome Sequencing Reveals Zoonotic LinksGenome sequencing of feline and canine Microsporum canis reveals close genetic identity to an invasive human strain and dissects secreted AZymes that drive keratin degradation and potential zoonosis.
2025-07-27 12:06:26
Microsporum canis Antifungal Susceptibility Testing: Methods, Variability, and Clinical ImplicationsThis review outlines therapeutic strategies and susceptibility profiles for Microsporum canis, highlighting the need for standardized testing and noting poor efficacy for fluconazole and griseofulvin. Terbinafine and itraconazole remain preferred options.
2025-07-27 11:41:15
Zinc and Microsporum canis: Targeting ZafA to Disrupt Fungal VirulenceZinc deficiency significantly impairs Microsporum canis growth and virulence. The A gene regulates zinc uptake and pathogenesis, and its deletion disrupts zinc transporters, conidiation, and host infection, suggesting it as a novel antifungal drug target.
2025-07-27 10:35:37
M. canis Antifungal Resistance: Enzymatic Correlates and Drug EfficacyThis study identified catalase and hemolysin as key virulence factors linked to antifungal resistance in Microsporum canis strains from symptomatic hosts. Voriconazole, terbinafine, and posaconazole were most effective.
2025-07-27 10:19:43
Microsporum canis Antifungal Resistance Confirmed by PCR and Susceptibility TestingThis case study confirmed Microsporum canis infection in cats through CR and identified high antifungal resistance, with only itraconazole proving effective. These findings highlight the growing need for antifungal susceptibility testing in zoonotic dermatophytosis.
2025-07-27 09:44:30
Antifungal Activity of Compound 2d Against Dermatophytes via Ergosterol Pathway DisruptionThis study identified compound 2d as a potent antifungal agent against dermatophytes, demonstrating efficacy via ergosterol pathway suppression, cell wall disruption, and oxidative stress induction. It was non-toxic to mammalian cells, making it a strong candidate for further antifungal drug development.
2025-07-27 09:30:34
Dermatophyte Virulence and Host Immunity: Key Mechanisms and Clinical ImplicationsThis review outlines the pathogenic strategies of dermatophytes and host antifungal responses, with a focus on keratinolytic enzymes, RRs, Th17 immunity, and ARD9-related immune dysfunction, offering insight into novel diagnostic and therapeutic strategies.
2025-07-27 08:24:48
Microsporum canis Antifungal Susceptibility and Therapy: A ReviewThis review evaluates antifungal susceptibility and therapeutic options for Microsporum canis, highlighting methodological variability in testing and identifying terbinafine and itraconazole as the most reliable agents.